A Pilot Study to Examine the Effects of an Anti-inflammatory Supplement on Eicosanoid Derivatives in Patients with Chronic Kidney Disease.

What Was Tested

This randomized controlled trial looks at Copper (Supplement).

Therefore, the purpose of this study was to study the effects of a supplement containing curcumin and B. serrata on eicosanoid derivatives in early stage CKD patients who had not initiated hemodialysis.

Why It Was Studied

Chronic kidney disease (CKD) is a progressive disease with an inverse relationship between kidney function and levels of inflammation and oxidative stress.

Curcumin and Boswellia serrata have been reported to exert anti-inflammatory effects on the cyclooxygenase and lipoxygenase pathways.

Who Took Part

By PubMed's age tags, the people studied were adults, middle-aged adults and older adults.

Sixteen patients with stage 2 and stage 3 CKD (56.0 ± 16.0 years, 171.4 ± 11.9 cm, 99.3 ± 20.2 kg) were randomized into a treatment group with curcumin and B. serrata or a placebo group.

How the Study Was Run

The design is described as randomized, placebo-controlled and pilot.

The participants were allocated by chance, so the Copper (Supplement) group and the comparison group should start out alike.

The comparison arm used a placebo, so changes seen with Copper (Supplement) could be set against what happens without it.

It is described as a pilot, a small early test of whether a larger Copper (Supplement) study would be practical.

Results were analyzed by using a repeated-measures analysis of covariance for compliance and body-mass index.

What Was Measured

Chronic kidney disease (CKD) is a progressive disease with an inverse relationship between kidney function and levels of inflammation and oxidative stress.

PubMed files the paper under topics including Anti-Inflammatory Agents, Boswellia, Curcumin, Dietary Supplements, Eicosanoids, Inflammation and Pilot Projects.

The authors tagged it with the keywords Boswellia serrata, chronic kidney disease and prostaglandins.

What This Means in Plain Language

The paper is a randomized, placebo-controlled and pilot study of Copper (Supplement).

Results are reported in around 4 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2017 (Journal of alternative and complementary medicine (New York, N.Y.)), a journal based in United States.

More context: the Copper (Supplement) compound page, all human trials.